<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002212</url>
  </required_header>
  <id_info>
    <org_study_id>287A</org_study_id>
    <secondary_id>L1069-21</secondary_id>
    <nct_id>NCT00002212</nct_id>
  </id_info>
  <brief_title>A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma</brief_title>
  <official_title>Phase II Evaluation of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ligand Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe and effective to give Targretin capsules to&#xD;
      patients with AIDS-related Kaposi's sarcoma (KS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label study to evaluate the safety and efficacy of Targretin&#xD;
      capsules in patients with AIDS-related KS. NOTE: The daily dose may be reduced as necessary&#xD;
      for toxicity management.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>27</enrollment>
  <condition>Sarcoma, Kaposi</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexarotene</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Serum HIV antibody positive by ELISA.&#xD;
&#xD;
          -  KS documented by biopsy (repeat biopsy is not required for entry if KS has been&#xD;
             previously confirmed histologically and the histopathology report has been reviewed).&#xD;
&#xD;
          -  A minimum of 6 mucocutaneous KS lesions, including at least 3 raised lesions, each of&#xD;
             which has been present for at least 30 days or has a longest dimension of at least&#xD;
             10mm, and has not received prior local or topical therapy within 60 days of study&#xD;
             entry.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Concurrent, serious, uncontrolled infection including, but not limited to:&#xD;
&#xD;
          -  Mycobacterium avium intracellulare or other mycobacterium infection; Pneumocystis&#xD;
             carinii pneumonia; CMV retinitis or colitis; Toxoplasma brain abscess; Cryptococcal&#xD;
             meningitis.&#xD;
&#xD;
          -  Serious intercurrent illness or infection that would interfere with the ability of the&#xD;
             patient to carry out the treatment program.&#xD;
&#xD;
          -  Known allergy or sensitivity to retinoid class drugs.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Local or topical therapy such as, but not limited to, Vitamin A, tretinoin&#xD;
             (all-trans-retinoic acid), other retinoid class drugs, or intralesional (injection)&#xD;
             therapy to any KS indicator lesion.&#xD;
&#xD;
          -  Systemic anticancer chemotherapy, systemic anticancer hormonal therapy, and/or&#xD;
             systemic anticancer immunotherapy.&#xD;
&#xD;
          -  Systemic use of retinoid class drugs, beta-carotene compounds, or Vitamin A in doses&#xD;
             greater than 15,000 IU (5,000 mcg) per day (equivalent to approximately 3 times the&#xD;
             RDA) for any indication.&#xD;
&#xD;
          -  Human chorionic gonadotropin.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Radiotherapy, cryotherapy, photodynamic therapy, and/or laser therapy for any KS indicator&#xD;
        lesion.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Systemic treatment of KS within 30 days of study entry.&#xD;
&#xD;
          -  Systemic treatment with either Vitamin A in doses greater than 15,000 IU (5,000 mcg)&#xD;
             per day (equivalent to approximately 3 times the RDA) or other retinoid class drugs&#xD;
             for any indication within 30 days of study entry.&#xD;
&#xD;
          -  Previous local or topical therapy of any KS indicator lesion such as, but not limited&#xD;
             to, Vitamin A, tretinoin (all-trans-retinoic acid), other retinoid class drugs, or&#xD;
             intralesional (injection) therapy within 60 days of study entry.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiotherapy, cryotherapy, photodynamic therapy and/or laser therapy within 60 days of&#xD;
             study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Desert Univ School of Medicine</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton S Hershey Med Ctr</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1999</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Sarcoma, Kaposi</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Anticarcinogenic Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bexarotene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

